Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.
DOI: 10.3322/caac.21834
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008 Dec 10;26(35):5802-12.
DOI: 10.1200/JCO.2008.16.4368
Han K, Milosevic M, Fyles A, et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 2013;87:111–9.
DOI: 10.1016/j.ijrobp.2013.05.033
Shrivastava S, Mahantshetty U, Engineer R, et al. Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. JAMA Oncol 2018;4:506–13.
DOI: 10.1001/jamaoncol.2017.5179
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144–53.
DOI: 10.1056/NEJM199904153401502
Wright JD, Matsuo K, Huang Y, et al. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol 2019;134:49–57.
DOI: 10.1097/AOG.0000000000003311
Varia MA, Bundy BN, Deppe G, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1998;42:1015–23.
DOI: 10.1016/S0360-3016(98)00267-3
Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis ofa randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:1654–63.
DOI: 10.1016/S0140-6736(17)31607-0
Muñoz N et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
DOI: 10.1056/NEJMoa021641
Shah W, Yan X, Jing L, et al. A reversed CD4/ CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol 2011; 8: 59–66.
DOI: 10.1038/cmi.2010.56
Komdeur FL, Prins TM, van de Wall S, et al. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology 2017; 6: e1338230.
DOI: 10.1080/2162402X.2017.1338230
Martins PR, Machado CMT, Coxir SA, et al. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment. Exp Mol Pathol 2019; 111: 104314.
DOI: 10.1016/j.yexmp.2019.104314
Heeren AM, van Luijk IF, Lakeman J, et al. Neoadjuvant cisplatin and paclitaxel modulate tumor- infiltrating T cells in patients with cervical cancer. Cancer Immunol Immunother 2019; 68: 1759–1767.
DOI: 10.1007/s00262-019-02412-x
Huang RSP, et al. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Mod Pathol. 2021 Jul;34(7):1425-1433.
DOI: 10.1038/s41379-021-00780-3
Heeren AM, Punt S, Bleeker MC, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 2016; 29: 753–763.
DOI: 10.1038/modpathol.2016.64
Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019 Feb;51(2):202-206.
Cao J, et al. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. Transl Oncol. 2022 Jun;20:101375.
DOI: 10.1016/j.tranon.2022.101375
Cristescu R, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022 Jan;10(1):e003091.
DOI: 10.1136/jitc-2021-003091
Marabelle A, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-1365
DOI: 10.1016/S1470-2045(20)30445-9
Shao C, et al. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors. JAMA Netw Open. 2020 Oct 1;3(10):e2025109.
DOI: 10.1001/jamanetworkopen.2020.25109
Aurora-Garg D, Qiu AAP, et al. Large-scale evaluation of concordance of genomic scores in whole exome sequencing and Foundation Medicine comprehensive genomic platform across cancer types. J Immunoth Cancer 2019; 7: 318.
Ota N, et al. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. Jpn J Radiol. 2022 May;40(5):534-54.
DOI: 10.1007/s11604-021-01230-5
Tewari KS, et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022 Feb 10;386(6):544-555.
Frenel JS, et al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017 Dec 20;35(36):4035-4041
DOI: 10.1200/JCO.2017.74.5471
Chung HC, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478
DOI: 10.1200/JCO.18.01265
Oaknin A, et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. Lancet Oncol. 2024 May;25(5):588-602.
DOI: 10.1016/S1470-2045(24)00088-3
Salani R, et al. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). Int J Gynecol Cancer. 2024 Aug 5;34(8):1140-1148.
DOI: 10.1136/ijgc-2024-005588
Lee JY, Wu L, et al. 744MO AdvanTIG-202: phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC) Ann Oncol. 2023;34:S509–S510.
DOI: 10.1016/j.annonc.2023.09.1923
Birrer M, et al. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 25:e242145.
DOI: 10.1001/jamaoncol.2024.2145
Vergote IB, Gonzalez Martin A, Fujiwara K et al. innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Abstract presented at: ESMO Congress 2023, October 20-24, 2023
Vergote I, et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. J Clin Oncol. 2023 Dec 20;41(36):5536-5549.
DOI: 10.1200/JCO.23.00720
Oaknin, Ana et al. LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034). Gynecologic Oncology, Volume 166, S24
DOI: 10.1016/S0090-8258(22)01252-5
Gadducci, A., Tana, R., Cosio, S., & Cionini, L. (2010). Treatment options in recurrent cervical cancer (Review) . Oncology Letters, 1, 3-11.
DOI: 10.3892/ol_00000001
Huang H, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial. The Lancet 2017 Oct 7;390(10103):1654–63.37.
DOI: 10.1016/S0140-6736(17)31607-0
Colombo N, et al. KEYNOTE-826 Investigators. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021 Nov 11;385(20):1856-1867.
DOI: 10.1056/NEJMoa2112435
Monk BJ, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023 Dec 20;41(36):5505-5511.
DOI: 10.1200/JCO.23.00914
Oaknin A, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024 Jan 6;403(10421):31-43.
Lorusso D, et al. Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826. IJGC 2023;33:A1 ESGO 2023 Oral presentation.
DOI: 10.1136/ijgc-2023-ESGO.1
Lou H, et al. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clin Cancer Res. 2024 Apr 15;30(8):1501-1508.
DOI: 10.1158/1078-0432.CCR-23-3162
Mayadev JS, et al. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020 Jan 1;6(1):92-99.
DOI: 10.1001/jamaoncol.2019.3857
Da Silva DM, et al. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clin Cancer Res. 2020 Nov 1;26(21):5621-5630.
DOI: 10.1158/1078-0432.CCR-20-0776
Rodrigues M, et al. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial. Nat Commun. 2023;14:3698.
DOI: 10.1038/s41467-023-39383-8
Duska LR, et al. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2020 Nov 15;126(22):4948-4956.
DOI: 10.1002/cncr.33136
Monk BJ, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Dec;24(12):1334-1348.
DOI: 10.1016/S1470-2045(23)00479-5
Lorusso et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2024, Sept.
DOI: 10.1016/S0140-6736(24)01808-7
Garcia-Duran C, et al. ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation. Int J Gynecol Cancer. 2022 Apr 20:ijgc-2022-003370.
DOI: 10.1136/ijgc-2022-003370
Roussy,G.; Cancer Campus,Grand Paris. Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer; Clinical Trial Registration NCT03612791; clinicaltrials.gov. 2022. Available online: https://clinicaltrials.gov/ct2/show/NCT03612791 (accessed on 3 January 2023)
O’Cearbhaill et al. Safety and immunogenicity of Anti PD-L1 (Atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: an NRG Oncology trial (024). Gynecol Oncol. 2022;166(suppl 1):S18-S19.
DOI: 10.1016/S0090-8258(22)01242-2
Ray-Coquard I, et al. In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study. J Clin Oncol. 2023;41(16_suppl).
DOI: 10.1200/JCO.2023.41.16_suppl.5501
Nakamura K, et al. Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018. J Clin Oncol. 2023;41(16_suppl) 5514.
DOI: 10.1200/JCO.2023.41.16_suppl.5519
Li K, et al. Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(1):76-85.
DOI: 10.1016/S1470-2045(23)00531-4
Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, Li Q. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer. Front Oncol. 2022 Oct 10;12:990877.
DOI: 10.3389/fonc.2022.990877
Hato L, Vizcay A, Eguren I, Pérez-Gracia JL, Rodríguez J, Gállego Pérez-Larraya J, Sarobe P, Inogés S, Díaz de Cerio AL, Santisteban M. Dendritic Cells in Cancer Immunology and Immunotherapy. Cancers 2024, 16, 981
DOI: 10.3390/cancers16050981